{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:23:32Z","timestamp":1794471812092,"version":"4.9.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/P017339\/1"],"award-info":[{"award-number":["MR\/P017339\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N013468\/1"],"award-info":[{"award-number":["MR\/N013468\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["220679\/Z\/20\/Z"],"award-info":[{"award-number":["220679\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018694","name":"European Commission Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","award":["840866"],"award-info":[{"award-number":["840866"]}],"id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.vaccine.2025.127541","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T03:05:13Z","timestamp":1753499113000},"page":"127541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Rabies glycoprotein engineering for improved stability and expression"],"prefix":"10.1016","volume":"62","author":[{"given":"Solomon","family":"English","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofiya","family":"Fedosyuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Orliacq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Tem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawsad","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Q.","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Thorley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"L\u00f3pez-Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegund C.","family":"Ertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander D.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127541_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.cimid.2023.101992","article-title":"Canine rabies: an epidemiological significance, pathogenesis, diagnosis, prevention, and public health issues","volume":"97","author":"Kumar","year":"2023","journal-title":"Comp Immunol Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127541_bb0010","first-page":"1","article-title":"Rabies","volume":"3","author":"Fooks","year":"2017","journal-title":"Nat Rev Disease Primers 2017 3:1"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127541_bb0030","first-page":"262","article-title":"Research progress on neutralizing epitopes and antibodies for the rabies virus","volume":"1","author":"Shi","year":"2022","journal-title":"Inf Med"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127541_bb0035","doi-asserted-by":"crossref","first-page":"735","DOI":"10.20506\/rst.11.3.622","article-title":"Practical significance of rabies antibodies in cats and dogs","volume":"11","author":"Aubert","year":"1992","journal-title":"Rev Sci Tech"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127541_bb0040","doi-asserted-by":"crossref","first-page":"e663","DOI":"10.1016\/S2666-5247(22)00126-4","article-title":"Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-Centre, phase 1 clinical trial","volume":"3","author":"Jenkin","year":"2022","journal-title":"Lancet Microbe"},{"issue":"26","key":"10.1016\/j.vaccine.2025.127541_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126441","article-title":"Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adults","volume":"42","author":"Phadke","year":"2024","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127541_bb0050","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-55843-9","article-title":"Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label phase I study in healthy volunteers","volume":"16","author":"Maine","year":"2025","journal-title":"Nat Commun"},{"issue":"10101","key":"10.1016\/j.vaccine.2025.127541_bb0055","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127541_bb0060","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","article-title":"Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial","volume":"39","author":"Aldrich","year":"2021","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127541_bb0065","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1080\/21645515.2021.1957413","article-title":"Safety and immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: a randomized, comparator controlled, multicenter, phase III clinical study","volume":"17","author":"Ravish","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127541_bb0070","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrmicro.2018.11","article-title":"The spread and evolution of rabies virus: conquering new frontiers","volume":"16","author":"Fisher","year":"2018","journal-title":"Nature Reviews Microbiology"},{"key":"10.1016\/j.vaccine.2025.127541_bb0075","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.virusres.2019.02.006","article-title":"Early events in rabies virus infection\u2014attachment, entry, and intracellular trafficking","volume":"263","author":"Guo","year":"2019","journal-title":"Virus Res"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127541_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-14398-7","article-title":"Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein","volume":"11","author":"Hellert","year":"2020","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127541_bb0085","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.celrep.2016.03.067","article-title":"Improved monosynaptic neural circuit tracing using engineered rabies virus glycoproteins","volume":"15","author":"Kim","year":"2016","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127541_bb0090","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1348-0421.1999.tb02402.x","article-title":"Intracellular behavior of rabies virus matrix protein (M) is determined by the viral glycoprotein (G)","volume":"43","author":"Nakahara","year":"1999","journal-title":"Microbiol Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127541_bb0095","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1348-0421.2003.tb03458.x","article-title":"Characterization of a slow-migrating component of the rabies virus matrix protein strongly associated with the viral glycoprotein","volume":"47","author":"Nakahara","year":"2003","journal-title":"Microbiol Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127541_bb0100","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1128\/JVI.73.1.242-250.1999","article-title":"Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G","volume":"73","author":"Mebatsion","year":"1999","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127541_bb0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-023-00707-w","article-title":"Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery","volume":"8","author":"Liu","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127541_bb0110","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.136653","article-title":"Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation","volume":"5","author":"Kelly","year":"2020","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127541_bb0115","first-page":"1","article-title":"The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice","volume":"6","author":"Sun","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"309","key":"10.1016\/j.vaccine.2025.127541_bb0120","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4241","article-title":"Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera","volume":"7","author":"Ngwuta","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2025.127541_bb0125","series-title":"Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein","author":"McLellan","year":"2015"},{"issue":"35","key":"10.1016\/j.vaccine.2025.127541_bb0130","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6510","key":"10.1016\/j.vaccine.2025.127541_bb0135","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127541_bb0140","first-page":"119","article-title":"Mapping of epitopes and structural analysis of antigenic sites in the nucleoprotein of rabies virus","volume":"81","author":"Goto","year":"2000","journal-title":"J Gen Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127541_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006870","article-title":"A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis","volume":"12","author":"Wang","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127541_bb0150","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1128\/JVI.02568-07","article-title":"Single-dose protection against plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron a","volume":"82","author":"Sridhar","year":"2008","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127541_bb0155","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/30.2.e9","article-title":"High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells","volume":"30","author":"Durocher","year":"2002","journal-title":"Nucleic Acids Res"},{"issue":"15","key":"10.1016\/j.vaccine.2025.127541_bb0160","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.vaccine.2006.12.031","article-title":"Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates","volume":"25","author":"Sloan","year":"2007","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127541_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/df98339d-6bdb-40ed-af83-cc38b249264a","article-title":"Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans","volume":"3","author":"M\u00fcller","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127541_bb0170","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1128\/JVI.79.8.4672-4678.2005","article-title":"Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis","volume":"79","author":"Marissen","year":"2005","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127541_bb0175","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.vaccine.2007.10.064","article-title":"Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines","volume":"26","author":"Miura","year":"2008","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127541_bb0180","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","article-title":"Improving mRNA-based therapeutic gene delivery by expression-augmenting 3\u2019 UTRs identified by cellular library screening","volume":"27","author":"Orlandini von Niessen","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2025.127541_bb0185","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/B978-0-12-801919-1.00017-8","article-title":"The rapid fluorescent focus inhibition test","volume":"2","author":"Yager","year":"2015","journal-title":"Current Laboratory Techniques in Rabies Diagnosis, Research and Prevention"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127541_bb0190","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0022-1759(97)00212-3","article-title":"Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody","volume":"212","author":"Cliquet","year":"1998","journal-title":"J Immunol Methods"},{"issue":"36","key":"10.1016\/j.vaccine.2025.127541_bb0305","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1016\/j.vaccine.2014.06.058","article-title":"A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice","volume":"32","author":"Koraka","year":"2014","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127541_bb0310","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1073\/pnas.1308701110","article-title":"Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines","volume":"111","author":"Lu","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127541_bb0195","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2144\/000112993","article-title":"Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function","volume":"45","author":"Stanton","year":"2008","journal-title":"Biotechniques"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127541_bb0200","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1128\/JVI.02568-07","article-title":"Single-dose protection against plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron a","volume":"82","author":"Sridhar","year":"2008","journal-title":"J Virol"},{"issue":"19","key":"10.1016\/j.vaccine.2025.127541_bb0205","doi-asserted-by":"crossref","first-page":"28262","DOI":"10.18632\/oncotarget.8596","article-title":"Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab","volume":"7","author":"Xing","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127541_bb0210","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/bit.24342","article-title":"Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors","volume":"109","author":"Cottingham","year":"2012","journal-title":"Biotechnol Bioeng"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127541_bb0215","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jmb.2004.09.079","article-title":"Foldon, the natural trimerization domain of T4 fibritin, dissociates into a monomeric A-state form containing a stable beta-hairpin: atomic details of trimer dissociation and local beta-hairpin stability from residual dipolar couplings","volume":"344","author":"Meier","year":"2004","journal-title":"J Mol Biol"},{"issue":"5813","key":"10.1016\/j.vaccine.2025.127541_bb0220","first-page":"843","article-title":"Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G","volume":"315","author":"Roche","year":"2007","journal-title":"Science (1979)"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127541_bb0225","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.chom.2022.07.014","article-title":"Structure of trimeric pre-fusion rabies virus glycoprotein in complex with two protective antibodies","volume":"30","author":"Ng","year":"2022","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127541_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2105-14-S19-S1","article-title":"Disulfide by design 2.0: a web-based tool for disulfide engineering in proteins","volume":"14","author":"Craig","year":"2013","journal-title":"BMC Bioinformatics"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127541_bb0235","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.chom.2019.12.012","article-title":"Structural analysis of rabies virus glycoprotein reveals pH-dependent conformational changes and interactions with a neutralizing antibody","volume":"27","author":"Yang","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127541_bb0240","first-page":"E28","article-title":"Mechanism of membrane fusion induced by vesicular stomatitis virus G protein","volume":"114","author":"Kima","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127541_bb0245","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.coviro.2013.03.006","article-title":"Intermediate conformations during viral fusion glycoprotein structural transition","volume":"3","author":"Baquero","year":"2013","journal-title":"Curr Opin Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127541_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002556","article-title":"Characterization of monomeric intermediates during VSV glycoprotein structural transition","volume":"8","author":"Albertini","year":"2012","journal-title":"PLoS Pathog"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127541_bb0255","doi-asserted-by":"crossref","first-page":"7371","DOI":"10.1128\/jvi.70.11.7371-7378.1996","article-title":"Identification of amino acids controlling the low-pH-induced conformational change of rabies virus glycoprotein","volume":"70","author":"Gaudin","year":"1996","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127541_bb0260","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.str.2012.06.009","article-title":"A fluorescence-detection size-exclusion chromatography-based thermostability assay for membrane protein precrystallization screening","volume":"20","author":"Hattori","year":"2012","journal-title":"Structure"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127541_bb0280","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.vaccine.2024.01.057","article-title":"A rabies mRNA vaccine with H270P mutation in its glycoprotein induces strong cellular and humoral immunity","volume":"42","author":"Cao","year":"2024","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2025.127541_bb0285","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abp9151","article-title":"Structure of the rabies virus glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"8","author":"Callaway","year":"2022","journal-title":"Sci Adv"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127541_bb0290","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1348-0421.2006.tb03812.x","article-title":"Two different conformations of rabies virus glycoprotein taken under neutral pH conditions","volume":"50","author":"Irie","year":"2006","journal-title":"Microbiol Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127541_bb0295","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1128\/jvi.67.3.1365-1372.1993","article-title":"Low-pH conformational changes of rabies virus glycoprotein and their role in membrane fusion","volume":"67","author":"Gaudin","year":"1993","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127541_bb0265","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2270081","article-title":"A single immunization with core\u2013shell structured lipopolyplex mRNA vaccine against rabies induces potent humoral immunity in mice and dogs","volume":"12","author":"Wan","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2025.127541_bb0270","article-title":"An mRNA vaccine against rabies provides strong and durable protection in mice","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127541_bb0275","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2024.2389115","article-title":"A nucleoside-modified mRNA vaccine forming rabies virus-like particle elicits strong cellular and humoral immune responses against rabies virus infection in mice","volume":"13","author":"Liu","year":"2024","journal-title":"Emerg Microbes Infect"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127541_bb0300","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1128\/JVI.76.7.3374-3381.2002","article-title":"Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response","volume":"76","author":"Faber","year":"2002","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25008382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25008382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T03:23:02Z","timestamp":1766546582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25008382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":59,"alternative-id":["S0264410X25008382"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127541","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rabies glycoprotein engineering for improved stability and expression","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127541","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127541"}}